Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / HBSS probes Medline over FDA violations
Regulatory regulatory investigation

HBSS probes Medline over FDA violations

Analysis based on 6 articles · First reported Jul 01, 2026 · Last updated Jul 08, 2026

Sentiment
-40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Medline's stock price fell sharply, wiping out $2.2 billion in market cap. The investigation may lead to further legal and regulatory actions, potentially impacting investor confidence and the company's financial performance.

Pharmaceutical Medical Devices
Event Summary

Hagens Berman (HBSS) launched an investigation into United States — MedlinePlus (NASDAQ: MDLN) regarding whether the company misled investors about its manufacturing quality controls and compliance with FDA safety standards. The probe follows an FDA warning letter dated May 28, 2026, citing CGMP violations including repeated contamination incidents and failure to investigate. Medline's share price dropped significantly, erasing about $2.2 billion in market capitalization. The investigation focuses on whether Medline concealed systemic lapses in contamination protocols and failed to disclose that it had shut down certain facilities in October 2025 due to quality problems.

Key Actions
100 United States — Food and Drug Administration issued warning letter United States — MedlinePlus
80 United States — MedlinePlus shut down facilities
70 Hagens Berman launched investigation United States — MedlinePlus
Entities Involved
govactor
United States — MedlinePlus
Medline is the subject of the investigation and FDA warning; its stock lost $2.2 billion in market cap and faces potential legal liabilities.
Importance 100.0 Sentiment -70.0
govactor
United States — Food and Drug Administration
The FDA issued a warning letter to Medline citing manufacturing violations, which triggered the investigation and market decline.
Importance 80.0 Sentiment 0.0
priv
Hagens Berman
HBSS is leading the investigation into Medline, representing shareholders and seeking to uncover potential securities law violations.
Importance 60.0 Sentiment 0.0
per
James Boyle
James Boyle is the CEO of Medline who received the FDA warning letter; his leadership is under scrutiny regarding the quality control failures.
Importance 40.0 Sentiment -50.0
per
Reed Kathrein
Reed Kathrein is the HBSS partner leading the investigation, acting as a key figure in the shareholder probe.
Importance 30.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The SEC's whistleblower program is mentioned as a potential avenue for reporting, but the SEC is not directly involved in the investigation.
Importance 20.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Hagens Berman
United States — Food and Drug Administration related ↔ Reed Kathrein
United States — Food and Drug Administration related ↔ United States — United States Securities and Exchange Commission
Hagens Berman related ↔ Reed Kathrein
Hagens Berman related ↔ United States — United States Securities and Exchange Commission
Reed Kathrein related ↔ United States — United States Securities and Exchange Commission
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.